Abstract
Anemia in heart failure is both common and associated with worse symptoms and increased mortality. Several small randomized controlled trials (RCTs) have assessed erythropoiesis-stimulating agents (ESAs), but definitive evaluation and clinical guidance are required. We sought to systematically review the effects of ESAs in chronic heart failure.
| Original language | English |
|---|---|
| Pages (from-to) | 822-831.e2 |
| Journal | American Heart Journal |
| Volume | 161 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2011 |
Keywords
- Anemia
- Erythropoietin
- Heart Failure
- Humans
- Randomized Controlled Trials as Topic
- Treatment Outcome